Literature DB >> 12865398

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.

Michael R Jacobs1, David Felmingham, Peter C Appelbaum, Reuben N Grüneberg.   

Abstract

OBJECTIVES: The Alexander Project is a continuing surveillance study, begun in 1992, examining the susceptibility of pathogens involved in adult community-acquired respiratory tract infections (CARTI) to a range of antimicrobial agents.
MATERIALS AND METHODS: This study tested the susceptibility of isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected between 1998 and 2000 to 23 antimicrobials. Minimum inhibitory concentrations of agents were determined using the broth microdilution method and interpreted according to NCCLS and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
RESULTS: In total, 8882 isolates of S. pneumoniae, 8523 isolates of H. influenzae and 874 isolates of M. catarrhalis were collected during 1998-2000 from centres in 26 countries. The world-wide prevalence of penicillin resistance (penicillin MICs > or = 2 mg/l) in isolates of S. pneumoniae was 18.2% over the study period, and the prevalence of macrolide resistance (erythromycin MICs > or = 1 mg/l) in this pathogen was 24.6%. Over the study period, macrolide resistance exceeded penicillin resistance in 19 of the 26 countries included in the study. Of the non-fluoroquinolone agents, the only oral agents to which over 90% of S. pneumoniae isolates were susceptible at both NCCLS and PK/PD breakpoints were amoxicillin (95.1%) and co-amoxiclav (95.5-97.9%). The prevalence of fluoroquinolone-resistant S. pneumoniae (ofloxacin MICs > or = 8 mg/l) was 1.1%. Gemifloxacin was the most potent fluoroquinolone tested against S. pneumoniae (99.9% susceptible). In isolates of H. influenzae, beta-lactamase production was 16.9%, whereas the prevalence of beta-lactamase-negative, ampicillin-resistant strains was low (0.2%). beta-Lactamase production in M. catarrhalis world-wide remained high over the period studied (92.1%). Using PK/PD breakpoints, the most active non-fluoroquinolone agents against H. influenzae were ceftriaxone (100% susceptible), cefixime (99.8%) and co-amoxiclav (98.1-99.6%). Co-amoxiclav, cefdinir and cefixime (100%) were the most active beta-lactams against M. catarrhalis. Both H. influenzae and M. catarrhalis were highly susceptible to the fluoroquinolones.
CONCLUSIONS: These data demonstrate the continued evolution of and geographical variation in bacterial resistance and highlight the need for appropriate prescribing of antimicrobials in CARTI, using agents with adequate activity, based on local susceptibility profiles and PK/PD parameters.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865398     DOI: 10.1093/jac/dkg321

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  124 in total

1.  Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Authors:  Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 2.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

3.  Distribution of subclasses mefA and mefE of the mefA gene among clinical isolates of macrolide-resistant (M-phenotype) Streptococcus pneumoniae, viridans group streptococci, and Streptococcus pyogenes.

Authors:  Carmen Ardanuy; Fe Tubau; Josefina Liñares; María Angeles Domínguez; Román Pallarés; Rogelio Martín
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media.

Authors:  Janet R Casey; Stan L Block; Jim Hedrick; Anthony Almudevar; Michael E Pichichero
Journal:  Drugs       Date:  2012-10-22       Impact factor: 9.546

5.  Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

Authors:  Pawel Grzesiowski; Raquel Aguiar-Ibáñez; Aleksandra Kobryń; Laure Durand; Pierre-Emmanuel Puig
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

6.  Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.

Authors:  Catherine L Clark; Klaudia Kosowska-Shick; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

Review 7.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.

Authors:  M Raquel Marín Jiménez; Juan Luis Muñoz Bellido; José Angel García Rodríguez
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Bacterial resistance surveillance in China: a report from Mohnarin 2004-2005.

Authors:  Y H Xiao; J Wang; Y Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-19       Impact factor: 3.267

10.  Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs.

Authors:  K Kosowska; M R Jacobs; S Bajaksouzian; L Koeth; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.